Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/6/16  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Jonathan Ratner

Wrong Dr. Jonathan Ratner?

Senior Economist

Phone: (301) ***-****  
Westat Inc
1650 Research Blvd.
Rockville , Maryland 20850
United States

Company Description: Westat is an employee-owned research corporation consulting in statistical design, data collection and management, and research analysis work. It is recognized as...   more
Background

Employment History

  • Assistant Professor of Economics
    Wellesley College
  • Assistant Professor
    Welles
  • Economist and Assistant Director and Associate Director
    GAO

Board Memberships and Affiliations

Education

  • PhD
16 Total References
Web References
What's New in Clinical Trials at Westat
www.westat.com [cached]
06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.
What's New in Clinical Trials at Westat
www.westat.org [cached]
06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.
What's New in Clinical Trials at Westat - 2010 News Archive
www.westat.com [cached]
06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.
Westat | Clinical Trials |2010 News, Awards, Presentations
www.westat.com [cached]
06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.
Westat | Clinical Trials |2010 News, Awards, Presentations
www.westat.com [cached]
06/07/2010 Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
...
Jonathan Ratner, Ph.D., Presents Paper at Pharmacoeconomics Meeting
Jonathan Ratner, Ph.D., gave a presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting in Atlanta, Georgia, on May 18, 2010.
Dr. Ratner is a Westat senior economist specializing in health and labor topics. He took part in an ISPOR Issues Panel, Pragmatic Clinical Trials: How Broad Is Too Broad and How Early Is Too Early? Dr. Ratner's presentation for the panel was titled, Pragmatic Clinical Trials: Health Care Payers' Views of PCT Features and Trade-offs.
Pragmatic clinical trials (PCTs) are a relatively new variant of traditional randomized clinical trials (RCTs). In an RCT-usually funded by a pharmaceutical manufacturer-researchers test a new drug against a placebo. The drug manufacturer makes the RCT's results available to the U.S. Food and Drug Administration (FDA), which approves the new drug for use if convinced that the drug is safe and effective. "However," Dr. Ratner explained, "health care payers-private insurers and public payers such as the Defense Department-typically want to know more than what most RCTs tell them.
...
Dr. Ratner and a colleague interviewed formulary decisionmakers at private and public payers. These decisionmakers described their views of PCTs and discussed the trade-offs they would make if cost considerations forced trial sponsors to choose between, for example, a broader patient population and an active (non-placebo) comparator. Dr. Ratner's preliminary study results are part of a project for a commercial client.
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304